List of Kerendia drug patents

Kerendia is owned by Bayer Hlthcare.

Kerendia contains Finerenone.

Kerendia has a total of 1 drug patent out of which 0 drug patents have expired.

Kerendia was authorised for market use on 09 July, 2021.

Kerendia is available in tablet;oral dosage forms.

Drug patent challenges can be filed against Kerendia from July, 2025.

The generics of Kerendia are possible to be released after 12 April, 2029.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8436180 BAYER HLTHCARE Substituted-4-aryl-1,4-dihydro-1,6-naphthyridinamides and use thereof
Apr, 2029

(6 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jul 9, 2026
M Sep 1, 2025

Drugs and Companies using FINERENONE ingredient

NCE-1 date: July, 2025

Market Authorisation Date: 09 July, 2021

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in